Biotech News Alert: GenSpera (OTCQB:GNSZ) Announces Generic Name “Mipsagargin” for Lead Drug Candidate G-202 per Recommendation by World Health Organization
Mipsagargin Contains New Pre-Stem “Gargin”, Defining a Unique Pharmacologic Group Unlike Any Drug Currently or Previously on the Market
SAN ANTONIO, Texas, September 3, 2014 – (Investorideas.com Biotech Newswire) GenSpera, Inc. ( ... Read more
Four Stocks Competing in the Medical Aesthetic Market; (NYSE: $AGN), (OTCQB: $REPCF) (TSXV: $RP), (NASDAQ: $HOLX), (ZLTQ)
Point Roberts, WA, -April 25, 2017 – Investorideas.com, a global news source covering biotech and medical technology, issues a sector close–up on publicly traded companies competing in the rapidly growing medical aesthetic market.
According to a new report published by Allied Market Research, titled, Blood Gas and Electrolyte Analyzers Market by Type, Product/Brand, and End User: Global Opportunity Analysis and Industry Forecast, 2017-2023, the global blood gas and electrolyte analyzers market was valued at $1,427 million in 2016, and is projected to garner $2,104 million by 2023, registering a CAGR of 5.7% from 2017 to 2023. The consumables segment accounted for the highest market share in 2016, ... Read more
Manufacturing cell therapies is technically and financially demanding; as a result, despite therapy developers gradually strengthening their in-house expertise, they are also becoming increasingly reliant on contract service providers
Roots Analysis is pleased to announce the publication of its recent study, titled, “ ... Read more
The approval of KYMIRAH®, YESCARTA®, Alofisel® and Zyntelgo® has increased the interest of pharma stakeholders in cell therapies; further, owing to the technical challenges in this field, outsourcing manufacturing operations has become a necessity
Screening small molecule fragments has made it possible to identify pharmacological leads against otherwise hard to target hotspots on biomolecules, such as allosteric sites, rendering this approach a valuable alternative method of drug discovery
Roots Analysis is pleased to announce the publication of its recent study, titled, “ ... Read more
Roots Analysis has done a detailed report on Companion Diagnostics Development Services Market covering key aspects of the industry and identifying future growth opportunities
To order this 320+ page report, which features 120+ figures and 115+ tables, please visit this link
Manufacturing highly potent drug products is technically and financially demanding; as a result, drug manufacturers are becoming increasingly reliant on contract service providers
In the last couple of years, a record number of personalized therapeutic products were approved in the US, establishing an urgent need for companion diagnostics and causing many drug developers to actively seek external support and expertise
Roots Analysis is pleased to announce the publication of its recent study, titled, “ ... Read more
The numerous benefits offered by prefilled syringes, coupled to the growing self-medication trend, have led to the approval of a number of drugs in combination with such devices, resulting in an increase in need to outsource fill / finish operations
Roots Analysis is pleased to announce the publication of its recent study, titled, “ ... Read more
The approval of KYMIRAH®, YESCARTA®, Alofisel® and Zyntelgo® has increased the interest of pharma stakeholders in cell therapies; further, owing to the technical challenges in this field, outsourcing manufacturing operations has become a necessity
To order this detailed 380+ page report, please visit this link
Key Inclusions
A detailed assessment of the current market landscape of psychedelic therapeutics, providing information on phase of development (commercial, clinical, preclinical, and discovery stage) of lead candidates, type of
Significant advancements in the developmental pipeline across various oncological disorders, infectious diseases and genetic disorders have amplified the interest of various pharmaceutical establishments and have inspired research groups across the world, to focus their efforts on the development of RNAi therapeutics. Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years. ... Read more
To order this 350+ page report, which features 130+ figures and 190+ tables, please visit this link
Key Inclusions
A detailed review of the overall landscape of companies developing RNAi therapeutics, including information on phase of development (marketed, clinical, and
To order this detailed 500+ page report, please visit this link
Key Inclusions
A detailed assessment of the current market landscape featuring over 280 stem cell-based therapies approved / under clinical development, including information on drug / therapy developer(s) (such as year of establishment,
There is a growing body of evidence supporting the vast applicability and superiority of treatment outcomes of stem cell therapies, compared to conventional treatment options. In fact, the unmet needs within this domain have spurred the establishment of many start-ups in recent years. Further, recent studies suggest that mesenchymal stem cells mesenchymal stem cells can be effectively used to improve patients' resistance to the SARS-CoV-2 virus induced pneumonia leading to speedy
The potential therapeutic applications of RNAi were realized almost immediately after the phenomenon was first described; over the years, developers have gradually progressed their proprietary drug candidates with cautious optimism
Roots Analysis is pleased to announce the publication of its recent study, titled, “ ... Read more
With multiple approved products, the field of stem cell therapies has gained substantial momentum over the last decade; several innovator companies are currently progressing their proprietary therapy candidates with cautious optimism.In fact, recent studies suggest that mesenchymal stem cells have the potential to end the Coronavirus (COVID-19) pandemic.
Advances in screening technologies have enabled the identification of interactive gene combinations, enabling the development of lead candidates that leverage the principle of synthetic lethality for cancer treatment
To order this 485+ page report, which features 195+ figures and 200+ tables, please visit this
Advances in molecular screening technology have enabled the identification of novel synthetic lethal gene combinations, enabling the development of lead candidates that leverage the aforementioned phenomenon to offer therapeutic benefit.
Roots Analysis is pleased to announce the publication of its recent study, titled, “ ... Read more
A detailed assessment of the current market landscape, providing information on drug developer(s) (year of establishment, headquarters and size of the company), phase of development (marketed, clinical, preclinical, and discovery stage) of lead candidates, type of molecule (small molecule and biologic), type of therapy (monotherapy and combination therapy), type of synlet target, target patient segment, key therapeutic area(s), target
Subcutaneous drug delivery, given the use of tailored formulation development solutions, has brought about a paradigm shift in at-home healthcare, enabling users to administer (life-saving) medications without having to rely on medical professionals
Roots Analysis is pleased to announce the publication of its recent study, titled “ ... Read more
